Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
1 other identifier
observational
85
1 country
2
Brief Summary
The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways. De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2008
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 11, 2009
CompletedFirst Posted
Study publicly available on registry
February 12, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
April 13, 2026
April 1, 2026
20.1 years
February 11, 2009
April 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Factors in dermatologic diseases.
Evaluate the role of angiogenesis in cutaneous disease and ultimately, facilitate implementation of anti-angiogenic therapy in a wide range of dermatologic diseases including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea and psoriasis.
up to 4 weeks
Study Arms (1)
dermatologic diseases
skin tissue sample
Interventions
Eligibility Criteria
Tissue samples will be collected from Dermatopathology Lab, Pathology lab, discarded tissue from dermatologic surgery at University of California Irvine. Additional biopsies may be obtained of known lesions.
You may qualify if:
- years of age or older.
- willing to have a skin biopsy
You may not qualify if:
- under 16 years of age
- unable to carry out instructions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Beckman Laser Institute and Medical Clinic
Irvine, California, 92697, United States
Dermatology Clinic at Gavin Herbert Eye Institute
Irvine, California, 92697, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kristen Kelly, MD
University of California, Irvine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Dermatology
Study Record Dates
First Submitted
February 11, 2009
First Posted
February 12, 2009
Study Start
November 1, 2008
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2028
Last Updated
April 13, 2026
Record last verified: 2026-04